Moody Lynn & Lieberson LLC Purchases 2,657 Shares of Eli Lilly and Company $LLY

Moody Lynn & Lieberson LLC lifted its position in Eli Lilly and Company (NYSE:LLY) by 3.3% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 83,620 shares of the company’s stock after purchasing an additional 2,657 shares during the quarter. Eli Lilly and Company comprises 4.8% of Moody Lynn & Lieberson LLC’s holdings, making the stock its 5th largest position. Moody Lynn & Lieberson LLC’s holdings in Eli Lilly and Company were worth $89,865,000 at the end of the most recent quarter.

A number of other institutional investors also recently bought and sold shares of the business. Capital Research Global Investors raised its holdings in shares of Eli Lilly and Company by 20.9% during the third quarter. Capital Research Global Investors now owns 25,088,371 shares of the company’s stock worth $19,141,787,000 after purchasing an additional 4,332,008 shares during the last quarter. Amundi boosted its stake in shares of Eli Lilly and Company by 27.1% in the third quarter. Amundi now owns 4,525,902 shares of the company’s stock worth $3,823,977,000 after buying an additional 964,675 shares during the last quarter. Victory Capital Management Inc. raised its position in Eli Lilly and Company by 47.6% during the third quarter. Victory Capital Management Inc. now owns 2,309,006 shares of the company’s stock valued at $1,761,772,000 after acquiring an additional 744,868 shares in the last quarter. Danske Bank A S purchased a new stake in Eli Lilly and Company in the 3rd quarter worth approximately $512,022,000. Finally, Capital International Investors boosted its position in Eli Lilly and Company by 6.1% in the 3rd quarter. Capital International Investors now owns 10,001,509 shares of the company’s stock worth $7,628,447,000 after purchasing an additional 579,381 shares in the last quarter. 82.53% of the stock is owned by hedge funds and other institutional investors.

Key Eli Lilly and Company News

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: FDA approved Lilly’s oral GLP?1 weight?loss pill Foundayo (orforglipron), enabling a commercial launch (via LillyDirect) and broader patient access—this is the main growth catalyst behind recent investor enthusiasm. FDA approves Lilly’s Foundayo (PR Newswire)
• Positive Sentiment: Bank of America and other sell?side notes see Foundayo as a durable commercial opportunity (BofA called it a preferred oral GLP?1); BofA also raised its price target and reiterated a Buy rating, supporting medium?term analyst optimism. Bank of America sees Foundayo as preferred oral GLP-1
• Positive Sentiment: Street estimates see a multi?billion dollar debut for Foundayo (analyst scenarios ~ $1.5B–$2.8B in 2026) and unusually large call?option activity indicates speculative positioning for further upside from the drug launch. Foundayo Launch Could Drive Up to $2.8B (Blockonomi)
• Neutral Sentiment: Lilly agreed to acquire Centessa (deal value reported around $7.8B), diversifying Lilly’s pipeline into sleep/neuroscience — strategic for long?term growth but adds near?term integration and price?premium risk. LLY to Buy Centessa Pharmaceuticals (Zacks)
• Negative Sentiment: Policy risk: the Trump administration is proposing steep tariffs on branded drugs for companies that haven’t struck pricing deals—this raises regulatory and margin uncertainty for big pharma, including Lilly. Trump Administration Unveils Up to 100% Tariff on Branded Drugs (WSJ)
• Negative Sentiment: Competitive/marketing noise: Novo Nordisk published cross?trial comparisons claiming its oral Wegovy outperformed Foundayo, and media debate over efficacy/side?effect differences is tempering some investor enthusiasm. Novo says Wegovy pill outperforms Lilly’s Foundayo (CNBC)

Analyst Upgrades and Downgrades

A number of analysts recently issued reports on LLY shares. BMO Capital Markets reissued an “outperform” rating and set a $1,300.00 price target on shares of Eli Lilly and Company in a report on Thursday, February 5th. Morgan Stanley restated an “overweight” rating and issued a $1,313.00 price target on shares of Eli Lilly and Company in a research note on Thursday, March 5th. Zacks Research cut Eli Lilly and Company from a “strong-buy” rating to a “hold” rating in a report on Friday, January 30th. Deutsche Bank Aktiengesellschaft reissued a “buy” rating and issued a $1,285.00 price target on shares of Eli Lilly and Company in a research note on Friday, March 6th. Finally, Cantor Fitzgerald increased their price objective on shares of Eli Lilly and Company from $985.00 to $1,205.00 and gave the company an “overweight” rating in a report on Thursday, February 5th. Two investment analysts have rated the stock with a Strong Buy rating, twenty-three have given a Buy rating, four have issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $1,222.22.

Eli Lilly and Company Stock Down 2.0%

Eli Lilly and Company stock opened at $935.85 on Friday. The company has a market capitalization of $884.21 billion, a PE ratio of 40.78, a price-to-earnings-growth ratio of 1.11 and a beta of 0.51. The company has a debt-to-equity ratio of 1.54, a quick ratio of 1.19 and a current ratio of 1.58. Eli Lilly and Company has a fifty-two week low of $623.78 and a fifty-two week high of $1,133.95. The firm has a 50 day moving average price of $996.24 and a 200 day moving average price of $966.65.

Eli Lilly and Company (NYSE:LLY) last released its quarterly earnings results on Wednesday, February 4th. The company reported $7.54 EPS for the quarter, topping analysts’ consensus estimates of $7.48 by $0.06. Eli Lilly and Company had a return on equity of 102.94% and a net margin of 31.66%.The company had revenue of $19.29 billion for the quarter, compared to analysts’ expectations of $17.85 billion. During the same period in the prior year, the firm earned $5.32 earnings per share. The firm’s revenue was up 42.6% compared to the same quarter last year. Eli Lilly and Company has set its FY 2026 guidance at 33.500-35.000 EPS. Research analysts expect that Eli Lilly and Company will post 23.48 earnings per share for the current year.

Eli Lilly and Company Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.